Personalis

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Personalis and other ETFs, options, and stocks.

About PSNL

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives.

CEO

Christopher M. Hall

CEOChristopher M. Hall

Employees

260

Employees260

Headquarters

Fremont, California

HeadquartersFremont, California

Founded

2011

Founded2011

Employees

260

Employees260

PSNL Key Statistics

Market cap

1.61B

Market cap1.61B

Price-Earnings ratio

-15.13

Price-Earnings ratio-15.13

Dividend yield

—

Dividend yield—

Average volume

6.04M

Average volume6.04M

High today

$16.50

High today$16.50

Low today

$15.18

Low today$15.18

Open price

$15.96

Open price$15.96

Volume

6.62M

Volume6.62M

52 Week high

$16.50

52 Week high$16.50

52 Week low

$3.84

52 Week low$3.84

Stock Snapshot

With a market cap of 1.61B, Personalis(PSNL) trades at $15.40. The stock has a price-to-earnings ratio of -15.13.

On 2026-07-19, Personalis(PSNL) stock moved within a range of $15.18 to $16.50. With shares now at $15.40, the stock is trading +1.4% above its intraday low and -6.7% below the session's peak.

Trading activity shows a volume of 6.62M, compared to an average daily volume of 6.04M.

The stock's 52-week range extends from a low of $3.84 to a high of $16.50.

PSNL News

Investor's Business Daily 2d

Merck Reportedly Goes To Bat In Takeover Battle. Genomics Stock Flies.

Technology Merck Reportedly Goes To Bat In Takeover Battle. Genomics Stock Flies. Licensing Personalis (PSNL) stock popped Friday on a rumor Merck (MRK) and at...

Investing.com 2d

Needham raises Personalis stock price target on takeover interest - Investing.com

...

TipRanks 2d

Personalis price target raised to $17 from $12 at Needham

Needham raised the firm’s price target on Personalis (PSNL) to $17 from $12 and keeps a Buy rating on the shares following a blog report that the company has re...

Analyst ratings

86%

of 7 ratings

Buy

85.7%

Hold

14.3%

Sell

More PSNL News

TipRanks 2d

Analyst Raises Personalis Price Target to $17 on Heightened Takeover Prospects and Maintains Buy Rating

Personalis, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham assigned a Buy rating on the stock...

TipRanks 5d

Personalis’ NeXT Personal test granted UKCA marking

Personalis (PSNL) has achieved UKCA – United Kingdom Conformity Assessed – marking for its NeXT Personal Dx test. This critical regulatory milestone enables the...

People also own

Based on the portfolios of people who own PSNL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.